JP3496625B2 - Health food composition - Google Patents

Health food composition

Info

Publication number
JP3496625B2
JP3496625B2 JP2000147246A JP2000147246A JP3496625B2 JP 3496625 B2 JP3496625 B2 JP 3496625B2 JP 2000147246 A JP2000147246 A JP 2000147246A JP 2000147246 A JP2000147246 A JP 2000147246A JP 3496625 B2 JP3496625 B2 JP 3496625B2
Authority
JP
Japan
Prior art keywords
propolis
echinacea
extract
food composition
health food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000147246A
Other languages
Japanese (ja)
Other versions
JP2001046017A (en
Inventor
雄彦 佐藤
敏 三島
美穂 田中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunstar Inc
API Co Ltd
Original Assignee
Sunstar Inc
API Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunstar Inc, API Co Ltd filed Critical Sunstar Inc
Priority to JP2000147246A priority Critical patent/JP3496625B2/en
Publication of JP2001046017A publication Critical patent/JP2001046017A/en
Application granted granted Critical
Publication of JP3496625B2 publication Critical patent/JP3496625B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【発明の詳細な説明】 【0001】 【産業上の利用分野】本発明は、日々の健康を維持しさ
らに生活習慣病の予防・治療が可能な健康食品組成物に
関する。 【0002】 【従来の技術】従来、特定の症状や疾病の症状を緩和さ
せたり、予防的に作用する健康食品は数多く知られてき
ている。しかしながら、体全体の恒常性を高め、健康の
増進や生活習慣病の予防・治療が充分に可能な健康食品
は知られていない。 【0003】プロポリスは蜂の巣から採取される樹状物
質であるが、フラボノイド類、p−クマル酸や桂皮酸等
の有機酸やそのエステル、各種ミネラル、ビタミン類等
が含まれていて抗菌作用、抗酸化作用、制癌作用等のあ
ることが知られている。そのようなプロポリスは伝承的
に特定疾病の予防・治療に用いられてきた。 【0004】 【発明が解決しようとする課題】このようなプロポリス
は癌などの特定の症状や疾病に対しては効果があるが、
体全体の恒常性を高めて健康増進に寄与し、また現代人
にとって深刻な高血圧症、糖尿病、心臓病、肝臓病など
の生活習慣病を広く予防・治療することはできない。 【0005】 【課題を解決するための手段】本発明者らはプロポリス
に、エキナセアを組み合わせ摂取することにより、それ
ぞれ単独摂取した時には発揮されなかった効果が相乗的
に得られ、健康の増進や生活習慣病の予防・治療が達成
されるとの知見を得て本発明に至った。 【0006】 本発明は、プロポリス、エキナセア及び
ヒメマツタケを配合し、かつプロポリスとエキナセアの
配合比率が3:1〜1:3である健康食品組成物を提供
するものである。ヒメマツタケはその抽出物であってよ
い。本発明の健康食品組成物は、錠剤、あるいはソフト
カプセルなどのカプセル剤とすることができる。エキナ
セアは免疫力を高める作用のあることは従来知られてい
るが、プロポリスと組み合わせて摂取することにより、
相乗的に体全体の恒常性を高めて健康の増進や生活習慣
病の予防・治療に効果を示すことは知られていない。 【0007】 【発明の詳細な開示】以下に、本発明を詳細に説明す
る。 【0008】(プロポリス)本発明にて用いられるプロ
ポリスは、通常のプロポリス又はその抽出物であればよ
く、産地、製法等が特に限定されるものではない。プロ
ポリス抽出物は、プロポリス原塊からエタノール、水、
グリセリンなどを抽出溶媒として用いて、公知の方法に
より抽出することができる。得られた抽出物は、さらに
沈殿物を除去するなど精製を行ってもよい。さらに、こ
の抽出液体を濃縮した濃縮物や乾固させたものであって
もよく、デキストリン、無水結晶マルトース、デンプン
などの賦形剤と混合して粉末の形態としたものであって
もよい。賦形剤により粉末化する場合、賦形剤と抽出物
との割合(賦形剤:抽出物)は、5:1〜1:2であるの
が好ましい。 【0009】(エキナセア)本発明にて用いられるエキ
ナセア由来の成分は、菊科の植物であるEchinaceapurpu
rea、Echinacea pallida、Echinacea angustifolia、Ec
hinacea simulata、Echinacea paradoxa又はEchinacea
atrorubensの全草又は茎又は根の乾燥粉末、搾汁液又は
種々の抽出溶媒、例えば水、エタノールなどによる抽出
物である。この抽出物は、プロポリス抽出物の場合と同
様、さらに精製、濃縮、乾固を行った物であってもよ
く、粉末化したものであってもよい。粉末化にあたり賦
形剤を使用する場合、賦形剤と抽出物との使用割合は前
記と同様である。 【0010】プロポリスとエキナセアとの配合比率は、
プロポリス:エキナセア=10:1〜1:10が適当で
あるが、望ましくはプロポリス:エキナセア=3:1〜
1:3である。 【0011】(他の添加成分)本発明の食品組成物に
は、さらにヒメマツタケ、霊芝、シリマリン、乳酸菌、
ビフィズス菌など適宜他の健康食品素材を組み合わせて
配合してもよい。特にヒメマツタケ(Agaricus blazei m
urrill)の子実体や菌糸体を熱水抽出した抽出物には、
抗腫瘍活性があることが報告されている。この抽出物
は、前記と同様、さらに精製、濃縮、乾固を行った物で
あってもよく、粉末化したものであってもよい。粉末化
にあたり賦形剤と抽出物との使用割合も前記と同様であ
る。 【0012】ヒメマツタケエキスを加える場合、プロポ
リスとエキナセアの混合物合計量に対し、ヒメマツタケ
抽出物を10重量%以上で添加するのが好ましい。この
抽出物を併用することによりさらに免疫賦活作用を高め
て、体全体の恒常性を保つことができる。 【0013】(カプセル化)本発明の食品組成物は、錠
剤、カプセル剤、飲料、トローチ、チュアブル剤、ガム
など種々の適宜の剤型として提供することができ、特に
カプセル剤、錠剤が好ましい。プロポリスは本来は不快
な匂いを発するが、ゼラチンなどの適宜の皮膜を用い
て、公知の方法によりソフトカプセルに加工することに
より不快臭が気にならない程度にまで改良することがで
きる。また、ソフトカプセルでは原材料が直接酸素と接
触しないため、錠剤より成分の酸化による劣化が少な
く、製造後の品質保持期限を長くすることができ、プロ
ポリスを用いた食品形状としては最も望ましい。 【0014】かかるソフトカプセルを製造するには、公
知のソフトカプセル皮膜用原料(例えば、ゼラチン:グ
リセロール:精製水=42:18:40)を60〜65
℃で加温溶解し、常法に従って調製する。 【0015】ソフトカプセルの内容物は、抽出液体の濃
縮物、乾固物、粉末化したもの、あるいはこれらを食用
油脂、ミツロウなどの分散媒に分散してもよい。 【0016】前記分散媒に有効成分を分散したソフトカ
プセルの内容液を調製するには、これら原料を混合後6
5〜75℃加温して攪拌、溶解を行い、減圧脱気した後
冷却して調製する。このようにして調製した内容液を用
いて、例えばロータリー式ソフトカプセル製造装置など
を用い、常法に従って涙型など種々のソフトカプセル、
その他のカプセル剤を製造することができる。なお、分
散媒に用いる食用油脂としては、サフラワー油、大豆
油、ゴマ油などが挙げられ、特にサフラワー油が好まし
い。かかるカプセル内容物中の有効成分の配合量は、1
5〜40重量%、好ましくは20〜35重量%である。
なお、1カプセル中におけるプロポリスとエキナセアの
合計の含有量は、40〜160mg、好ましくは80〜
120mgである。 【0017】(錠剤)発明の食品組成物では前記粉末化し
た各成分、又は必要により造粒した各成分を打錠し、口
の中で噛まずに摂取することが望ましい。プロポリスに
は不快な特有に臭いがあるので錠剤はシェラックコート
や糖衣を設けるのが好ましい。また臭いの強いプロポリ
ス成分のみをマイクロカプセル状に加工した上で、錠剤
に加工してもよい。 【0018】本発明の健康食品組成物を錠剤の形態にす
るには、公知の打錠方法がいずれも用いられてよい。す
なわち、プロポリス粉末及びエキナセア粉末、また必要
に応じてヒメマツタケ粉末、さらには賦形剤、甘味剤、
香料、着色剤、滑沢剤など適宜の添加成分を加え、公知
の打錠機を用い錠剤の形態の健康食品組成物とすること
ができる。かかる錠剤中の有効成分の配合量は20〜8
0重量%、好ましくは40〜60重量%である。賦形剤
としては、粉末還元麦芽糖、乳糖、結晶セルロースなど
が使用され、錠剤中の賦形剤配合量は、20〜80重量
%、好ましくは40〜60重量%である。錠剤には通常
滑沢剤が用いられ、滑沢剤としてはショ糖脂肪酸エステ
ルが一般的である。錠剤中の滑沢剤配合量は1〜5重量
%、好ましくは2〜4重量%である。 【0019】 【実施例】つぎに、本発明を実施例によりさらに具体的
に説明する。 【0020】[実施例1]表1に示すソフトカプセルサン
プル(毎日4カプセル)をボランテイア30人に1年間継
続摂取してもらいアンケート調査を行った。その結果を
表2に示す。 【0021】 【表1】 【0022】 【表2】 【0023】[実施例2]試験に供したソフトカプセルの
内容物組成を表3に示す。原材料を加温しながら均一に
混合し、ゼラチン皮膜によりカプセル状に加工した。 【0024】 【表3】 【0025】健常成人30名をランダムに3群に分け、
冬の12月より2ヶ月間、前記試験品B、C、Dを各群
10人にそれぞれ1日に6カプセルずつ摂取させた。試
験終了後に流行性感冒に関するアンケート調査を行い、
表4の結果を得た。 【0026】 【表4】 【0027】結果は該当した項目の合計人数で示した。
表4に示すように、プロポリスとエキナセアを組み合わ
せた試験品Bは、流行性感冒の症状を訴えた人数がプロ
ポリス単独の試験品Cやエキナセア単独の試験品Dより
も少ないことが確かめられた。 【0028】[実施例3]高血圧抑制効果を調べた結果を
示す。15週齢の雄性高血圧ラット(SHR)24匹を標準
飼料を用いて1週間予備飼育をした後、体重及血圧を測
定し、それらが均等になるように1群6匹として4群に
振り分けた。標準飼料は株式会社船橋農場製のSPを用
いた。実験飼料を各群それぞれ8週間摂取させ、2週間
毎に血圧を調べた結果を表5に示す。 【0029】 【表5】 【0030】各群間の摂食量及び体重に有意な差は認め
られなかった。血圧の測定は、無麻酔下で尾動脈圧測定
装置(UR1000,UEDA)を用いて測定した。6週目、8週目
において、プロポリス/エキナセア併用群においての有
意な血圧上昇抑制が認められた。 【0031】[実施例4]表6に示す原料を均一に混合し
打錠機を使って錠剤に加工した。なお、必要に応じて造
粒してから打錠を行ってもよく、錠剤にシェラックコー
トや糖衣を施してもよい。 【0032】 【表6】 【0033】[実施例5]白血病発症抑制効果を調べた結
果を下記の表7に示す。胸腺リンパ腫形成に伴う白血病
を自然発症する5週齢のAKR/Jマウス60匹を標準
飼料で1週間予備飼育をした後、体重が均等になるよう
に1群12匹として5群に振り分けた。実験試料を各群
それぞれ摂取させてから、48週にわたり死亡個体数を
観察した。各飼料は自由摂食させた。 【0034】 【表7】【0035】死亡率100%になる時期は、対照群に比
べて、プロポリス群では4週遅く、エキナセア群では6
週遅く、プロポリス/エキナセア併用群では10週遅
く、プロポリス/エキナセア/ヒメマツタケ群では12
週遅い結果となった。これらの結果より、プロポリス/
エキナセア併用あるいは、プロポリス/エキナセア/ヒ
メマツタケの組み合わせが、白血病の発症を遅らせる作
用のあることがわかる。 【0036】[実施例6]肝機能改善効果を調べた結果を
下記の表9に示す。プロポリスエキス粉末、エキナセア
エキス粉末、及びヒメマツタケエキス粉末を含む表8に
示す錠剤試験品を、肝機能の要経過観察中のボランティ
ア12人に、1日6錠づつ2ヶ月継続摂取してもらっ
た。摂取前と摂取後に採血し、血清中の肝機能指標の改
善効果を調べた(表9)。AST及びALTは紫外部吸収
光光度法により測定し、γ−GTPはL−γ−グルタミ
ル−p−ニトロアニリド基質法により測定した。 【0037】 【表8】 【0038】 【表9】 【0039】肝機能指標のAST及びALTの有意な低
下が観察され、γ−GTPは低下傾向が観察された。 【0040】 【発明の効果】本発明の健康食品は、体全体の恒常性を
高めて健康増進に寄与し、現代人にとって深刻な高血圧
症、糖尿病、心臓病、肝臓病などの生活習慣病を広く予
防・治療する。
Description: BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a health food composition capable of maintaining daily health and further preventing and treating lifestyle-related diseases. [0002] Conventionally, many health foods that alleviate specific symptoms or symptoms of diseases or act preventively have been known. However, there is no known health food that can increase the homeostasis of the whole body and can sufficiently promote health and prevent / treat lifestyle-related diseases. Propolis is a dendritic substance collected from honeycomb, but contains flavonoids, organic acids such as p-coumaric acid and cinnamic acid and esters thereof, various minerals, vitamins, etc. It is known to have an oxidizing action, an anticancer action and the like. Such propolis has been traditionally used for the prevention and treatment of specific diseases. [0004] Such propolis is effective against specific symptoms and diseases such as cancer,
It contributes to health promotion by improving the homeostasis of the whole body, and cannot prevent or treat lifestyle-related diseases such as hypertension, diabetes, heart disease and liver disease that are serious for modern people. [0005] By taking a combination of echinacea and propolis together, the present inventors have synergistically obtained effects that were not exhibited when each was taken alone, promoting health and life. The present inventors have obtained knowledge that prevention / treatment of habitual diseases can be achieved, and have reached the present invention. The present invention relates to propolis , echinacea and
Containing himematsutake, propolis and echinacea
Compounding ratio of 3: 1 to 1: Ru der provides a health food composition is 3. Himematsutake is its extract
Yes. The health food composition of the present invention can be made into capsules such as tablets or soft capsules. Echinacea is known to have an effect of enhancing immunity, but when taken in combination with propolis,
It is not known that it synergistically increases the homeostasis of the whole body and is effective in promoting health and preventing / treating lifestyle-related diseases. DETAILED DESCRIPTION OF THE INVENTION The present invention is described in detail below. (Propolis) The propolis used in the present invention may be an ordinary propolis or an extract thereof, and the production area, production method and the like are not particularly limited. Propolis extract is obtained from ethanol, water,
It can extract by a well-known method, using glycerol etc. as an extraction solvent. The obtained extract may be further purified by removing precipitates. Further, it may be a concentrate obtained by concentrating this extraction liquid or a dried product, or it may be mixed with an excipient such as dextrin, anhydrous crystalline maltose, starch or the like in the form of a powder. When powdered with an excipient, the ratio of the excipient to the extract (excipient: extract) is preferably 5: 1 to 1: 2. (Echinacea) The component derived from Echinacea used in the present invention is Echinaceapurpu, a chrysanthemum plant.
rea, Echinacea pallida, Echinacea angustifolia, Ec
hinacea simulata, Echinacea paradoxa or Echinacea
atrorubens whole plant or stem or root dry powder, juice or extract with various extraction solvents such as water, ethanol and the like. As in the case of the propolis extract, this extract may be further purified, concentrated and dried, or may be powdered. When an excipient is used for pulverization, the usage ratio of the excipient and the extract is the same as described above. The blending ratio of propolis and echinacea is:
Propolis: echinacea = 10: 1 to 1:10 is suitable, but desirably propolis: echinacea = 3: 1
1: 3. (Other additive components) The food composition of the present invention further includes himematsutake, ganoderma, silymarin, lactic acid bacteria,
You may mix | blend suitably other health food materials, such as a bifidobacterium, suitably. In particular, Agaricus blazei m
(urrill) fruit bodies and mycelium are extracted with hot water,
It has been reported to have antitumor activity. This extract may be purified, concentrated and dried as described above, or may be powdered. The ratio of the excipient and the extract used in pulverization is the same as described above. In the case of adding the matsutake mushroom extract, it is preferable to add the himematsutake extract in an amount of 10% by weight or more based on the total amount of the mixture of propolis and echinacea. By using this extract in combination, the immunostimulatory effect can be further enhanced and the homeostasis of the whole body can be maintained. (Encapsulation) The food composition of the present invention can be provided in various appropriate dosage forms such as tablets, capsules, beverages, troches, chewables and gums, and capsules and tablets are particularly preferred. Propolis originally emits an unpleasant odor, but it can be improved to such an extent that an unpleasant odor does not matter by processing it into a soft capsule by a known method using an appropriate film such as gelatin. In soft capsules, since the raw material does not come into direct contact with oxygen, the deterioration due to oxidation of the components is less than that of tablets, and the quality retention time after production can be extended, which is most desirable as a food form using propolis. For producing such soft capsules, a known raw material for soft capsule film (for example, gelatin: glycerol: purified water = 42: 18: 40) is used in an amount of 60 to 65.
Dissolve by warming at 0 ° C and prepare according to conventional methods. The contents of the soft capsule may be an extract liquid concentrate, a dried solid product, a powdered product, or these may be dispersed in a dispersion medium such as edible oil or beeswax. In order to prepare a soft capsule content liquid in which an active ingredient is dispersed in the dispersion medium, these raw materials are mixed and then mixed.
The mixture is heated at 5 to 75 ° C., stirred and dissolved, degassed under reduced pressure, and then cooled and prepared. Using the content liquid prepared in this way, for example, using a rotary soft capsule manufacturing apparatus, various soft capsules such as a tear mold according to a conventional method,
Other capsules can be produced. Examples of edible oils and fats used for the dispersion medium include safflower oil, soybean oil, sesame oil and the like, and safflower oil is particularly preferable. The compounding amount of the active ingredient in the capsule content is 1
It is 5 to 40% by weight, preferably 20 to 35% by weight.
In addition, the total content of propolis and echinacea in one capsule is 40 to 160 mg, preferably 80 to
120 mg. (Tablets) In the food composition of the invention, it is desirable to tablet each of the powdered components or, if necessary, granulated components, and take them without chewing them in the mouth. Since propolis has a peculiar smell that is unpleasant, tablets are preferably provided with a shellac coat or sugar coating. Alternatively, only a strong odor propolis component may be processed into a microcapsule and then processed into a tablet. Any known tableting method may be used to make the health food composition of the present invention into a tablet form. That is, propolis powder and echinacea powder, and if necessary, himematsutake powder, further excipients, sweeteners,
Appropriate additive components such as a fragrance, a colorant, and a lubricant are added, and a health food composition in the form of a tablet can be obtained using a known tableting machine. The compounding amount of the active ingredient in such tablets is 20-8.
0% by weight, preferably 40 to 60% by weight. As the excipient, powdered reduced maltose, lactose, crystalline cellulose and the like are used, and the excipient content in the tablet is 20 to 80% by weight, preferably 40 to 60% by weight. A lubricant is usually used for the tablet, and a sucrose fatty acid ester is generally used as the lubricant. The blending amount of the lubricant in the tablet is 1 to 5% by weight, preferably 2 to 4% by weight. Next, the present invention will be described more specifically with reference to examples. [Example 1] A questionnaire survey was conducted with 30 volunteers taking the soft capsule samples shown in Table 1 (4 capsules daily) for one year. The results are shown in Table 2. [Table 1] [Table 2] [Example 2] Table 3 shows the composition of the contents of the soft capsules used in the test. The raw materials were mixed uniformly while heating, and processed into a capsule shape with a gelatin film. [Table 3] Thirty healthy adults are randomly divided into three groups,
For two months from December in winter, the test products B, C, and D were each ingested by 6 capsules of 6 capsules per day. After the test, we conducted a questionnaire survey about the epidemic cold,
The results of Table 4 were obtained. [Table 4] The results are shown in terms of the total number of applicable items.
As shown in Table 4, it was confirmed that the test product B combining propolis and echinacea had fewer people who complained of symptoms of epidemic cold than the test product C using propolis alone or the test product D using echinacea alone. [Example 3] The results of examining the antihypertensive effect are shown. Twenty-four 15-week-old male hypertensive rats (SHR) were preliminarily raised for one week using a standard diet, and then body weight and blood pressure were measured. . The standard feed used was SP manufactured by Funabashi Farm. Table 5 shows the results of ingesting the experimental feed for each group for 8 weeks and examining the blood pressure every 2 weeks. [Table 5] There were no significant differences in food intake or body weight between the groups. The blood pressure was measured using a tail artery pressure measuring device (UR1000, UEDA) without anesthesia. At 6th and 8th weeks, significant suppression of blood pressure increase was observed in the propolis / echinacea combination group. [Example 4] The raw materials shown in Table 6 were uniformly mixed and processed into tablets using a tableting machine. Tableting may be performed after granulation as necessary, and shellac coat or sugar coating may be applied to the tablet. [Table 6] [Example 5] Table 7 shows the results of examining the leukemia inhibitory effect. Sixty 5-week-old AKR / J mice that spontaneously develop leukemia associated with thymic lymphoma formation were preliminarily raised on a standard diet for 1 week, and then divided into 5 groups as 12 mice per group so that their body weights were equal. After ingesting experimental samples in each group, the number of dead individuals was observed over 48 weeks. Each feed was fed ad libitum. [Table 7] The mortality rate of 100% was 4 weeks later in the propolis group than in the control group, and 6% in the echinacea group.
Late in the week, 10 weeks later in the propolis / echinacea combination group, 12 in the propolis / echinacea / himematsutake group
The result was a week later. From these results, propolis /
It can be seen that the combination of echinacea or the combination of propolis / echinacea / himematsutake has the effect of delaying the onset of leukemia. [Example 6] The results of examining the effect of improving liver function are shown in Table 9 below. Twelve volunteers who were in the course of observing the progress of liver function were continuously ingested 6 tablets a day for 2 months with the tablet test products shown in Table 8 containing propolis extract powder, echinacea extract powder, and himematsutake extract powder. Blood was collected before and after ingestion, and the effect of improving the liver function index in serum was examined (Table 9). AST and ALT were measured by ultraviolet absorption photometry, and γ-GTP was measured by L-γ-glutamyl-p-nitroanilide substrate method. [Table 8] [Table 9] A significant decrease in AST and ALT of the liver function index was observed, and a tendency for γ-GTP to decrease was observed. The health food of the present invention contributes to the promotion of health by increasing the homeostasis of the whole body, and the lifestyle-related diseases such as hypertension, diabetes, heart disease and liver disease that are serious for modern people. Widely prevent and treat.

フロントページの続き (56)参考文献 特開 平7−274896(JP,A) 特開 平10−234319(JP,A) 登録実用新案3053921(JP,U) (58)調査した分野(Int.Cl.7,DB名) A23L 1/30 A23L 1/076 A61K 35/78 JSTPlus(JOIS)Continuation of front page (56) References JP 7-274896 (JP, A) JP 10-234319 (JP, A) Registered utility model 3059321 (JP, U) (58) Fields surveyed (Int. Cl 7 , DB name) A23L 1/30 A23L 1/076 A61K 35/78 JSTPlus (JOIS)

Claims (1)

(57)【特許請求の範囲】 【請求項1】 プロポリス、エキナセア及びヒメマツタ
ケを配合し、かつプロポリスとエキナセアの配合比率が
3:1〜1:3である健康食品組成物。
(57) [Claims] [Claim 1] Propolis , Echinacea and Himematsu
The blend ratio of propolis and echinacea
A health food composition that is 3: 1 to 1: 3 .
JP2000147246A 1999-05-31 2000-05-19 Health food composition Expired - Fee Related JP3496625B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2000147246A JP3496625B2 (en) 1999-05-31 2000-05-19 Health food composition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11-151265 1999-05-31
JP15126599 1999-05-31
JP2000147246A JP3496625B2 (en) 1999-05-31 2000-05-19 Health food composition

Publications (2)

Publication Number Publication Date
JP2001046017A JP2001046017A (en) 2001-02-20
JP3496625B2 true JP3496625B2 (en) 2004-02-16

Family

ID=26480567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000147246A Expired - Fee Related JP3496625B2 (en) 1999-05-31 2000-05-19 Health food composition

Country Status (1)

Country Link
JP (1) JP3496625B2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1297751A1 (en) * 2001-10-01 2003-04-02 Bogar AG Composition to be administered orally
KR100488513B1 (en) * 2002-05-10 2005-05-11 에스티케이제약 주식회사 healthy food including propolis and the composition thereof
CN1778315A (en) * 2005-05-28 2006-05-31 淮北市辉克药业有限公司 Eijknisia flower honey and oral liquid
JP2007159511A (en) * 2005-12-15 2007-06-28 Atsushi Umemura Health food and health tea
IT1397225B1 (en) * 2009-12-30 2013-01-04 Nm Tech Nanomaterials And Microdevices Technology Ltd BACTERICIDAL AND VIRUCID COMPOSITION FOR THE ORAL CABLE
WO2018016455A1 (en) * 2016-07-19 2018-01-25 株式会社山田養蜂場本社 Nourishing tonic

Also Published As

Publication number Publication date
JP2001046017A (en) 2001-02-20

Similar Documents

Publication Publication Date Title
JP2002154977A (en) Composition for drinking and eating
US20160375073A1 (en) Composition for treatment or prevention of obesity, containing water extracts of fomitella fraxinea
KR20170099539A (en) Sedum composition promoting antioxidant and alcohol oxidation
JP3496625B2 (en) Health food composition
KR100828069B1 (en) Composition for preventing or treating fatty liver disease comprising fucoxanthin or marine plant extract containing same
JP6133471B2 (en) Xanthine oxidase inhibitor
JPH10265397A (en) Agent for preventing obesity
KR20020092082A (en) Tonic composition
WO2012140894A1 (en) Pharmaceutical composition
JP2020080803A (en) Spice, bonito extract and kelp extract-containing composition
JP2005170836A (en) Marine alga extract and lipase inhibitor containing the same
TWI334783B (en) Pharmaceutical composition for facilitating the reduction of blood-alcohol concentration after alcohol intake
KR102433586B1 (en) Food composition for relieving hangover and improving hepatic function
KR19980085889A (en) Obesity-controlled health food containing extracts of copper, red beans, multileaf and upper limb
JPH1149690A (en) Composition for stimulating lipolysis
JP2005089374A (en) Food and drink having function for preventing increase in blood glucose level
KR101521341B1 (en) Composition for prevention or treatment of anorexia comprising menispermum dauricum DC, menispermum dauricum DC extract, menispermum dauricum DC sludge or menisperum dauricum DC malt fermented liquid extract
JP4323128B2 (en) Bioactive composition
JP2003002831A (en) Ameliorating agent for female hormone abnormality disorder
KR0137897B1 (en) Health food containing leaf of eucommia ulmoides oliver
AU2006347124B2 (en) Composition for preventing and/or treating itching containing component originating in the bark of tree belonging to the genus Acacia
JP4768105B2 (en) Oral composition
JP4359046B2 (en) Anti-stress agent
JP2006016340A (en) Blood uric acid level reduction agent having extract of punica granatum l. as active ingredient
JP2021031440A (en) Antitumor agent set having active oxygen removing agent containing low molecular antioxidizing compound derived from natural product and immunity activator derived from natural product which is used for enhancing macrophages and lymphocytes

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20031028

R150 Certificate of patent or registration of utility model

Ref document number: 3496625

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081128

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081128

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091128

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091128

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121128

Year of fee payment: 9

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121128

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141128

Year of fee payment: 11

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees